Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosis

被引:107
|
作者
Kuhle, J. [1 ]
Leppert, D. [1 ]
Petzold, A. [4 ,5 ]
Regeniter, A. [2 ]
Schindler, C. [3 ]
Mehling, M. [1 ]
Anthony, D. C. [6 ]
Kappos, L. [1 ]
Lindberg, R. L. P. [1 ]
机构
[1] Univ Basel Hosp, Dept Biomed & Neurol, CH-4031 Basel, Switzerland
[2] Univ Basel Hosp, Dept Lab Med, CH-4031 Basel, Switzerland
[3] Univ Basel Hosp, Inst Social & Prevent Med, CH-4031 Basel, Switzerland
[4] UCL Inst Neurol, Dept Neuroimmunol, London, England
[5] Free Univ Amsterdam, Med Ctr, Dept Neurol, Amsterdam, Netherlands
[6] Univ Oxford, Dept Pharmacol, Oxford OX1 2JD, England
基金
新加坡国家研究基金会; 英国生物技术与生命科学研究理事会; 英国医学研究理事会;
关键词
HUMORAL IMMUNE-RESPONSE; AXONAL DAMAGE MARKERS; CEREBROSPINAL-FLUID; BIOLOGICAL MARKERS; SYSTEM ATROPHY; PROTEIN-LEVELS; LIGHT-CHAIN; BLOOD; DEGENERATION; BIOMARKER;
D O I
10.1212/WNL.0b013e31821432ff
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: Neurodegeneration is now accepted as a pathologic hallmark of multiple sclerosis (MS). We sought to discover whether CSF levels of neurofilament heavy chain protein (NfH(SMI35)) correlate with disability, disease activity, or specific stages of MS. Methods: An electrochemiluminescence immunoassay was used to retrospectively measure NfHSMI35 in CSF of patients with clinically isolated syndrome (CIS) (n = 63), relapsing-remitting multiple sclerosis (RRMS) (n = 39), secondary progressive multiple sclerosis (SPMS) (n = 25), primary progressive multiple sclerosis (PPMS) (n = 23), or controls (n = 73). Cell count and CSF levels of immunoglobulin and albumin were also measured. Results: CSF levels of NfH(SMI35) increased with age in controls (r(s) = 0.50, p < 0.0001) and CIS (r(s) = 0.50, p < 0.0001); this effect was less pronounced in RRMS (r(s) = 0.35, p = 0.027) and absent in SPMS/PPMS. After age correction, NfH(SMI35) levels were found to be higher in all disease stages compared to control. Relapses were associated with higher CSF NfH(SMI35) values compared with stable disease. NfH(SMI35) levels correlated with EDSS scores in patients with CIS and RRMS (r(s) = 0.33, p = 0.001), and during relapse (r(s) = 0.35, p = 0.01); the correlation was most prominent in RRMS during relapse (r(s) = 0.54, p = 0.01). This was not the case for any of the other CSF markers examined. Conclusions: Neuronal loss is a feature of aging, and the age-dependent increase of CSF NfH(SMI35) suggests that this loss accelerates over time. For MS, increased NfH(SMI35) levels reflect the superimposed presence of further neurodegenerative processes. Evaluation of NfH(SMI35) levels is likely to provide a useful surrogate for measuring the rate of neurodegeneration in MS. Furthermore, the dissociation of NfH(SMI35) levels with biomarkers of inflammation suggests that the mechanisms responsible for their production are at least partly independent. Neurology (R) 2011;76:1206-1213
引用
收藏
页码:1206 / 1213
页数:8
相关论文
共 50 条
  • [41] Combined MRI lesions and relapses as a surrogate for disability in multiple sclerosis
    Sormani, M. P.
    Li, D. K.
    Bruzzi, P.
    Stubinski, B.
    Cornelisse, P.
    Rocak, S.
    De Stefano, N.
    NEUROLOGY, 2011, 77 (18) : 1684 - 1690
  • [42] Relapses add to permanent disability in relapsing multiple sclerosis patients
    Koch-Henriksen, Nils
    Sorensen, Per Soelberg
    Magyari, Melinda
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2021, 53
  • [43] Worsening of disability caused by relapses in multiple sclerosis: A different approach
    Koch-Henriksen, Nils
    Thygesen, Lau Caspar
    Sorensen, Per Soelberg
    Magyari, Melinda
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2019, 32 : 1 - 8
  • [44] Multiple sclerosis relapses contribute to long-term disability
    Scott, Thomas F.
    Diehl, Daniel
    Elmalik, Wisam
    Gettings, Edward J.
    Hackett, Chris
    Schramke, Carol J.
    ACTA NEUROLOGICA SCANDINAVICA, 2019, 140 (05): : 336 - 341
  • [45] Exploratory analysis of multiple sclerosis disability progression unrelated to relapses
    Kappos, L.
    Trojano, M.
    Butzkueven, H.
    Wiendl, H.
    Spelman, T.
    Pellegrini, F.
    Chen, Y.
    Dong, Q.
    Koendgen, H.
    Belachew, S.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 412 - 413
  • [46] Assessing disability and relapses in multiple sclerosis on tele-neurology
    Moccia, Marcello
    Lanzillo, Roberta
    Morra, Vincenzo Brescia
    Bonavita, Simona
    Tedeschi, Gioacchino
    Leocani, Letizia
    Lavorgna, Luigi
    NEUROLOGICAL SCIENCES, 2020, 41 (06) : 1369 - 1371
  • [47] Assessing disability and relapses in multiple sclerosis on tele-neurology
    Marcello Moccia
    Roberta Lanzillo
    Vincenzo Brescia Morra
    Simona Bonavita
    Gioacchino Tedeschi
    Letizia Leocani
    Luigi Lavorgna
    Neurological Sciences, 2020, 41 : 1369 - 1371
  • [48] Residual disability after multiple sclerosis relapses: the role of smoking
    Rojas, J. I.
    Miguez, J.
    Patrucco, L.
    Giunta, D.
    Cristiano, E.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 502 - 502
  • [49] Multiple sclerosis relapses: a multivariable analysis of residual disability determinants
    Vercellino, M.
    Romagnolo, A.
    Mattioda, A.
    Masera, S.
    Piacentino, C.
    Merola, A.
    Chi, A.
    Mutani, R.
    Cavalla, P.
    ACTA NEUROLOGICA SCANDINAVICA, 2009, 119 (02): : 126 - 130
  • [50] Heavy neurofilament phosphoforms in relapsing-remitting multiple sclerosis: correlation with MRI measures and clinical disability
    Annunziata, P.
    Cioni, C.
    De Santi, L.
    Stromillo, M. L.
    Di Perri, C.
    Federico, A.
    De Stefano, N.
    JOURNAL OF NEUROLOGY, 2006, 253 : 26 - 26